• Real-Time Tracking of mRNA-LNP Delivery Dynamics In Vivo

  2026-07-21

  This study illuminates the dynamic process of mRNA delivery by lipid nanoparticles (LNPs) in vivo, employing dual-mode imaging to directly observe biodistribution, release, and expression of mRNA. By leveraging advanced FRET-based tracking of Cy5-labeled luciferase mRNA, the research clarifies how LNP composition and administration route affect mRNA release and translation, informing the rational design and optimization of mRNA therapeutics.

• Cy3 NHS Ester (Non-Sulfonated): Technical Guide and Best Pra

  2026-07-21

  Cy3 NHS ester (non-sulfonated) provides a robust solution for fluorescent labeling of proteins, peptides, and oligonucleotides in workflows where organic co-solvents can be tolerated. It is optimal for sensitive detection in biomedical imaging but should not be used in strictly aqueous protocols or for labeling solvent-sensitive proteins.

• Ionomycin Free Acid: Mechanism and Benchmarks in Calcium Ion

  2026-07-20

  Ionomycin free acid is a selective calcium ionophore used to increase intracellular calcium concentrations in diverse cellular models. Its mechanism involves direct facilitation of Ca2+ transport across lipid bilayers, enabling applications in cell signaling, oocyte activation, and embryonic development research. This article details evidence, protocols, and practical limitations for research-grade use.

• Cy5-UTP: Advancing Mechanistic RNA Studies & Translational P

  2026-07-20

  This thought-leadership article unpacks how Cy5-UTP (Cyanine 5-UTP) bridges mechanistic RNA biology and translational innovation, drawing on new insights into axonal RNA trafficking and protein aggregation. Integrating cutting-edge research, experimental protocols, and strategic guidance, we reveal how Cy5-UTP empowers researchers to illuminate RNA dynamics in complex cellular contexts and chart a path toward impactful clinical applications.

• Phosphatase Inhibitor Cocktail 1: Precision in Protein Phosp

  2026-07-19

  Phosphatase Inhibitor Cocktail 1 (100X in DMSO) preserves phosphorylation states during sample prep, enabling high-fidelity phosphoproteomic and signaling pathway analyses. Its optimized formula, validated across Western blot, immunoprecipitation, and kinase assays, empowers researchers to capture transient phosphorylation events with confidence.

• Reliable Notch Pathway Modulation with DAPT (GSI-IX) in Cell

  2026-07-18

  This article examines real-world laboratory challenges in cell viability and differentiation assays, with a focus on how DAPT (GSI-IX) (SKU A8200) delivers robust, reproducible results. Drawing on quantitative data, scenario-driven Q&A, and peer-reviewed literature, we highlight the value of APExBIO's DAPT as a selective γ-secretase inhibitor for advanced research in Alzheimer's, cancer, and organoid modeling.

• Ionomycin Free Acid: Precision Calcium Modulation for FAK an

  2026-07-17

  Discover how Ionomycin free acid, a selective calcium ionophore, enables advanced control over intracellular calcium signaling in both cancer biology and reproductive research. This article uniquely connects FAK pathway modulation and embryonic development, offering actionable insights for cutting-edge assay design.

• EZ Cap™ Human PTEN mRNA (ψUTP): Optimized Workflows for Canc

  2026-07-17

  EZ Cap™ Human PTEN mRNA (ψUTP) from APExBIO sets a new standard for restoring tumor suppressor function using in vitro transcribed mRNA with advanced stability and immune evasion features. This article guides researchers through streamlined protocols, troubleshooting, and cutting-edge use-cases—drawing on landmark studies to translate molecular innovation into actionable lab results.

• Nanoparticle PTEN mRNA Delivery Reverses Trastuzumab Resista

  2026-07-16

  The reference study demonstrates that tumor microenvironment-responsive nanoparticles can systemically deliver PTEN mRNA to HER2-positive breast tumors, restoring PTEN function and reversing resistance to trastuzumab. This approach provides a mechanistically rational strategy for overcoming PI3K/Akt-driven therapy resistance in breast cancer.

• CORE LNPs Enable Selective Splenic mRNA Delivery via Cholest

  2026-07-16

  This study presents CORE lipid nanoparticles (LNPs) with structurally modified cholesterol analogs to achieve targeted mRNA expression in the spleen, overcoming the common hepatic tropism of standard LNPs. The findings highlight a rational, computationally guided approach for extrahepatic mRNA delivery, with implications for vaccines and immune therapies.

• Olsalazine Sodium in Cancer and Inflammation Research Workfl

  2026-07-15

  Olsalazine Sodium stands out as a potent mesalamine dimer for both cancer and inflammation models, enabling precise LTB4 chemotaxis inhibition and xenobiotic transport studies. This guide details validated workflows, troubleshooting strategies, and protocol optimizations for maximizing reproducibility, with insights drawn from recent advances in mosquito physiology and colorectal cancer research.

• Hydrocortisone in Translational Research: Workflows & Advanc

  2026-07-15

  Hydrocortisone stands out as a gold-standard glucocorticoid hormone for dissecting inflammation, stress response, and neuroprotection in both cellular and animal models. This article translates cutting-edge findings and real-world troubleshooting into actionable, reproducible workflows for researchers seeking robust, data-driven results.

• Helper-Polymer FNPs Enable Stable, Lung-Targeted mRNA Delive

  2026-07-14

  The referenced study introduces five-element nanoparticles (FNPs) incorporating poly(β-amino esters) (PBAEs) and DOTAP for lung-specific mRNA delivery with unprecedented stability after lyophilization. This innovation addresses major bottlenecks in mRNA therapeutic storage and delivery, with implications for expanding access and improving the practicality of mRNA-based treatments for pulmonary diseases.

• FAISL lncRNA Blocks FAK Proteolysis, Driving TNBC Progressio

  2026-07-14

  The referenced study uncovers a novel mechanism in triple negative breast cancer (TNBC) where the long noncoding RNA FAISL stabilizes FAK protein by blocking Calpain 2-mediated proteolysis, thereby promoting tumor progression and metastasis. These findings highlight FAISL as both a crucial regulator of FAK and a potential therapeutic target in aggressive breast cancers.

• PEGylated mRNA Lipoplexes for Tumor Vaccination: Efficacy an

  2026-07-13

  This study introduces a PEGylated mRNA lipoplex platform optimized for intravenous tumor vaccination, demonstrating robust antibody and cytotoxic T cell responses while minimizing off-target lung accumulation. The findings advance design principles for safer and more effective mRNA delivery systems in cancer immunotherapy.

16261 records 1/1085 page Next 12345 下5页 Last page